|Touchlight, a UK biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, has concluded a development and manufacturing pipeline agreement with Versameb, a Swiss pre-clinical stage company focused on discovering and developing ground-breaking RNA-based therapeutics. The agreement enables Versameb to use Touchlight’s proprietary doggybone DNA (dbDNA™) vector technology to support the development of its novel mRNA-based therapeutics. dbDNA™ is a minimal, linear, double stranded, covalently closed DNA vector which is produced through an enzymatic manufacturing process. It can accommodate genes of interest of more than 20kb and is linearly scalable, making it highly adaptable to support a range of genetic medicines. Versameb will use dbDNA technology for manufacturing and clinical supply of VMB-100 and other future pipeline products. VMB-100, Versameb’s lead candidate, is a potentially first-in-class regenerative treatment for stress urinary incontinence, which is expected to enter clinical development in the second half of 2022.